Spark Therapeutics, Inc. Common Stock
ONCE
ONCE was delisted on the 16th of December, 2019.
95 hedge funds and large institutions have $904M invested in Spark Therapeutics, Inc. Common Stock in 2015 Q1 according to their latest regulatory filings, with 95 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
37% more call options, than puts
Call options by funds: $885K | Put options by funds: $646K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$90.5M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$76.4M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$69.4M |
| 4 |
DM
Deerfield Management
New York
|
+$36.4M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$30.8M |
Top Sellers
ONCE Hedge Fund Activity: Q1 2015 in Review
95 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Spark Therapeutics, Inc. Common Stock (ONCE) for Q1 2015, worth a combined $904M.
Buyers outnumbered sellers: 95 funds opened new ONCE positions and 0 closed out — a net gain of 95 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $90.5M.
- 95 institutional investors held Spark Therapeutics, Inc. Common Stock (ONCE) as of Q1 2015, up from 0 in Q4 2014.
- Funds reported $904M of Spark Therapeutics, Inc. Common Stock stock for Q1 2015.
- 95 funds opened new Spark Therapeutics, Inc. Common Stock positions in Q1 2015 and 0 closed out, a net change of +95 holders.
- The largest Spark Therapeutics, Inc. Common Stock buyer in Q1 2015 was Fidelity Investments, an estimated $90.5M added.
Based on aggregated 13F filings for Q1 2015.